GPATCH1 Activators
GPATCH1 operate through a series of intracellular signaling pathways that converge on the modulation of protein kinase A (PKA) activity. Forskolin directly stimulates adenylate cyclase, which catalyzes the conversion of ATP to cyclic AMP (cAMP), a secondary messenger that serves as a crucial signal for the activation of PKA. The rise in cAMP levels triggered by forskolin thereby leads to the activation of PKA, which is known to phosphorylate various target proteins, including GPATCH1.
Other compounds, such as IBMX, rolipram, and anagrelide, increase intracellular cAMP by inhibiting phosphodiesterases, the enzymes responsible for cAMP degradation. IBMX is a broad-spectrum phosphodiesterase inhibitor, while rolipram and anagrelide are more selective, targeting phosphodiesterase 4 and phosphodiesterase III, respectively. By preventing cAMP breakdown, these inhibitors indirectly lead to PKA activation. Similarly, isoproterenol, terbutaline, epinephrine, and dopamine engage with specific adrenergic and dopaminergic receptors to stimulate adenylate cyclase, thereby boosting cAMP and activating PKA. Glucagon and PGE1 (Prostaglandin E1) also raise cAMP levels by interacting with their respective receptors, which are linked to adenylate cyclase activation. Histamine, through its action on H2 receptors, and cholera toxin, by permanently activating the Gs alpha protein, both result in an elevation of cAMP and subsequent PKA activation. Once activated, PKA can phosphorylate GPATCH1, an event that is central to the functional activation of the protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-specific inhibitor of phosphodiesterases, preventing cAMP breakdown, which indirectly leads to increased PKA activity. This amplification of PKA signaling could result in the phosphorylation and activation of GPATCH1. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), leading to increased cAMP levels in the cell. This increase can potentiate PKA activity, which in turn may lead to the phosphorylation and activation of GPATCH1. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that can elevate intracellular cAMP levels, thereby enhancing PKA activity. PKA could then phosphorylate and activate GPATCH1. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine interacts with beta-adrenergic receptors leading to increased cAMP and PKA activation. Activation of PKA may result in the phosphorylation and subsequent activation of GPATCH1. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine binds to its receptors, some of which can stimulate adenylate cyclase to increase cAMP production and PKA activity. PKA activation can then potentially lead to the phosphorylation and activation of GPATCH1. | ||||||
PGE1 (Prostaglandin E1) | 745-65-3 | sc-201223 sc-201223A | 1 mg 10 mg | $31.00 $145.00 | 16 | |
Prostaglandin E1 activates its receptor, which can increase cAMP levels in the cell, leading to PKA activation. This could facilitate the phosphorylation and activation of GPATCH1. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine can bind to H2 receptors which are positively coupled to adenylate cyclase, causing an increase in cAMP and subsequent PKA activation. PKA could then phosphorylate and activate GPATCH1. | ||||||
Terbutaline Hemisulfate | 23031-32-5 | sc-204911 sc-204911A | 1 g 5 g | $92.00 $378.00 | 2 | |
Terbutaline is a beta2-adrenergic agonist that increases cAMP levels in cells, leading to PKA activation. PKA may phosphorylate and functionally activate GPATCH1. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits phosphodiesterase III, leading to increased cAMP levels and PKA activation. Enhanced PKA activity could result in phosphorylation and activation of GPATCH1. | ||||||